Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Diane, Naselsky"'
Autor:
Steven D. Knight, Richard M. Keenan, James J. Foley, Diane Naselsky, Ralph A. Rivero, Kevin L. Salyers, Stephen A. Douglas, Anthony Sapienza, Nambi Aiyar, Ming An, Jian Jin, Dashyant Dhanak, Henry M. Sarau
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 18:3950-3954
SAR exploration of the central diamine, benzyl, and terminal aminoalkoxy regions of the N-cyclic azaalkyl benzamide series led to the identification of very potent human urotensin-II receptor antagonists such as 1a with a Ki of 4 nM. The synthesis an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4dd1b85ce899cd065d7316d03d052bf
https://doi.org/10.1016/j.bmcl.2008.06.019
https://doi.org/10.1016/j.bmcl.2008.06.019
Autor:
Richard M. Keenan, Henry M. Sarau, Nambi Aiyar, David J. Behm, Schmidt Stanley J, Lisa T. Christmann, Steven D. Knight, William E. Wixted, Lance Ridgers, Peter T. Buckley, Timothy Francis Gallagher, James J. Foley, Graham J. Riley, John G Gleason, Jyoti Disa, Diane Naselsky, Dashyant Dhanak, Stephen A. Douglas, Jian Jin, Widdowson Katherine L, Dulcie B. Schmidt, David P. Brooks, Eliot H. Ohlstein
Publikováno v:
British Journal of Pharmacology. 145:620-635
1. SB-706375 potently inhibited [(125)I]hU-II binding to both mammalian recombinant and 'native' UT receptors (K(i) 4.7+/-1.5 to 20.7+/-3.6 nM at rodent, feline and primate recombinant UT receptors and K(i) 5.4+/-0.4 nM at the endogenous UT receptor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::512cc94fd61162d159591dcd2189f2bc
https://doi.org/10.1038/sj.bjp.0706229
https://doi.org/10.1038/sj.bjp.0706229
Autor:
Jian Jin, Widdowson Katherine L, Dashyant Dhanak, Dulcie B. Schmidt, Henry M. Sarau, Nambi Aiyar, Richard M. Keenan, Stephen A. Douglas, Carl D. Bennett, Steven D. Knight, James J. Foley, Ralph A. Rivero, Diane Naselsky, Gregory L. Warren, Bing Wang, Michael L. Moore
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 15:3229-3232
High throughput screening of the corporate compound collection led to the discovery of a novel series of substituted aminoalkoxybenzyl pyrrolidines as human urotensin-II receptor antagonists. The synthesis, initial structure-activity relationships, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ae96515c41082ffce2c76c7a5f02392
https://doi.org/10.1016/j.bmcl.2005.04.074
https://doi.org/10.1016/j.bmcl.2005.04.074
Autor:
Nambi Aiyar, Diane Naselsky, Zhaohui Ao, Christopher L Herold, Frank Lynch, Stephen A. Douglas, Jyoti Disa
Publikováno v:
British Journal of Pharmacology. 142:921-932
1 In an effort to identify endogenous, native mammalian urotensin-II (U-II) receptors (UT), a diverse range of human, primate and rodent cell lines (49 in total) were screened for the presence of detectable [125I]hU-II binding sites. 2 UT mRNA (North
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e519430918a9e1dc2ccb774cfdc5a8ed
https://doi.org/10.1038/sj.bjp.0705743
https://doi.org/10.1038/sj.bjp.0705743
Autor:
Nambi Aiyar, Beverly E. Maleeff, Usman Shabon, Diane Naselsky, Zhaohui Ao, Stephen M. Harrison, Jyoti Disa, Stephen A. Douglas, Graham Duddy, Nabil Elshourbagy, Jan L. Sechler
Publikováno v:
British Journal of Pharmacology. 136:9-22
Urotensin-II (U-II) and its receptor (UT) represent novel therapeutic targets for management of a variety of cardiovascular diseases. To test such hypothesis, it will be necessary to develop experimental animal models for the manipulation of U-II/UT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4f83a8f55fadf3bbd88d021892c8412e
https://doi.org/10.1038/sj.bjp.0704671
https://doi.org/10.1038/sj.bjp.0704671
Autor:
Stephen A, Douglas, Diane, Naselsky, Zhaohui, Ao, Jyoti, Disa, Christopher L, Herold, Frank, Lynch, Nambi V, Aiyar
Publikováno v:
British journal of pharmacology. 142(6)
1 In an effort to identify endogenous, native mammalian urotensin-II (U-II) receptors (UT), a diverse range of human, primate and rodent cell lines (49 in total) were screened for the presence of detectable [125I]hU-II binding sites. 2 UT mRNA (North
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2d9ab1761a6a390c6f249883eca28876
https://pubmed.ncbi.nlm.nih.gov/15210573
https://pubmed.ncbi.nlm.nih.gov/15210573
Autor:
Diane Naselsky, Brian F. Guida, Stephen A. Douglas, Frederick C. Kull, Jyoti Disa, Nambi Aiyar, David J. Behm, Zhaohui Ao, Jui-Lan Su
Publikováno v:
Peptides. 25(8)
Plasma and urinary levels of “urotensin(U)-II-like” substances determined in healthy human volunteers were 12.4 ± 0.6 ng/ml and 2.2 ± 0.3 ng/ml by RIA, an order of magnitude lower than that seen by RRA, 167.5 ± 9.5 ng/ml and 65.2 ± 4.3 ng/ml.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::889bd7b8b98400a2076b60321bfcccc2
https://pubmed.ncbi.nlm.nih.gov/15350702
https://pubmed.ncbi.nlm.nih.gov/15350702
Autor:
Nabil A, Elshourbagy, Stephen A, Douglas, Usman, Shabon, Stephen, Harrison, Graham, Duddy, Jan L, Sechler, Zhaohui, Ao, Beverly E, Maleeff, Diane, Naselsky, Jyoti, Disa, Nambi V, Aiyar
Publikováno v:
British journal of pharmacology. 136(1)
Urotensin-II (U-II) and its receptor (UT) represent novel therapeutic targets for management of a variety of cardiovascular diseases. To test such hypothesis, it will be necessary to develop experimental animal models for the manipulation of U-II/UT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fd20dc4d992f0fee73be799465a91e9b
https://pubmed.ncbi.nlm.nih.gov/11976263
https://pubmed.ncbi.nlm.nih.gov/11976263